Q3 Earnings Forecast for Moderna Issued By Leerink Partnrs

Key Points

• Leerink Partners has cut its Q3 2025 earnings estimate for Moderna to ($2.33) per share, down from a previous estimate of ($1.90).
• Moderna's Q4 2025 earnings are now projected at ($3.12) EPS, with full-year earnings estimates for 2025 and 2026 at ($10.10) EPS and ($7.72) EPS respectively.
• Moderna's stock currently holds a consensus rating of "Hold" with a target price average of $45.61, while several analysts have adjusted their price targets between $25.00 and $32.00.

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Equities research analysts at Leerink Partnrs cut their Q3 2025 earnings estimates for shares of Moderna in a note issued to investors on Monday, August 4th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($2.33) per share for the quarter, down from their previous forecast of ($1.90). The consensus estimate for Moderna's current full-year earnings is ($9.61) per share. Leerink Partnrs also issued estimates for Moderna's Q4 2025 earnings at ($3.12) EPS, FY2025 earnings at ($10.10) EPS, FY2026 earnings at ($7.72) EPS, FY2027 earnings at ($4.95) EPS and FY2028 earnings at ($3.50) EPS.

MRNA has been the subject of several other research reports. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday. Bank of America reduced their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Barclays reduced their price target on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research report on Monday. Four analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $45.61.

Moderna Stock Performance

MRNA opened at $27.47 on Wednesday. The firm has a market cap of $10.69 billion, a P/E ratio of -3.65 and a beta of 1.83. The firm has a 50-day moving average of $29.27 and a 200 day moving average of $30.17. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm's revenue for the quarter was down 41.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.33) earnings per share.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently modified their holdings of the company. Corton Capital Inc. purchased a new stake in Moderna in the second quarter valued at approximately $475,000. State of Michigan Retirement System raised its stake in Moderna by 0.8% in the second quarter. State of Michigan Retirement System now owns 92,541 shares of the company's stock valued at $2,553,000 after purchasing an additional 700 shares in the last quarter. GAM Holding AG purchased a new stake in Moderna in the second quarter valued at approximately $276,000. Amalgamated Bank raised its stake in Moderna by 0.6% in the second quarter. Amalgamated Bank now owns 65,458 shares of the company's stock valued at $1,806,000 after purchasing an additional 408 shares in the last quarter. Finally, Assetmark Inc. raised its stake in Moderna by 137.7% in the second quarter. Assetmark Inc. now owns 1,298 shares of the company's stock valued at $36,000 after purchasing an additional 752 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.